Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age40-75
SponsorApeiron Research Center
About this trial
The purpose of this study is to measure outcomes using intranasal and intravenous autologous bone marrow mesenchymal stem cells (BM-MSCs) for Parkinson Disease (PD) and Parkinson's Plus (PPS) patients.
Eligibility criteria
Qualifiers
Participants aged 40-75 years old with a diagnosis of PD or PPS (DLB, PSP, MSA, CBD with parkinsonism) based upon clinical criteria and standardized testing
Participants time of documented PD or PPS is </= 6 years
Participants with an anticipated survival of at least 3 years in the investigator's opinion
Participants who are willing and able to give informed consent
Disqualifiers
Other non-PD/PPS Parkinsonism (e.g., drug-induced, vascular parkinsonism)
No strong familial history of PD/PPS not attributable to environmental exposure or any known genetic predisposition to PD/PPS
Unable to receive/tolerate neuroimaging (e.g., MRI-incompatible cardiac pacemaker)
Unable to maintain/tolerate supine position with cervical neck extension
Trial design
Treatments tested in this trial
- Autologous mesenchymal stem cells
Treatment groups
60 Participants
are divided into 4 treatment groupsLocations
Sponsors and collaborators
Apeiron Research Center
Lead sponsor
University of Colorado, Boulder
Collaborator
Source ClinicalTrials.gov